Bladder Carcinoma clinical trials
153 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Study of Surgical Techniques During Cystectomy
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
- Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
- Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
- Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
- Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
- Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
- Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
- Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
- A Phase I Intravesical PPM Therapy for NMIBC
- Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
- Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer
- Prophylactic Antibiotics in Cystectomy With Diversion
- Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
- Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
- A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
- A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of VET3-TGI in Patients With Solid Tumors
- AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Bladder Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.